Table 1. Study characteristics.

Study ID	Study design	Population	Intervention	Comparator	Follow-up	Primary outcome measure
Abbasi 2015 [43]	RCT	58 post-CABG MDD patients, 18-50yo, baseline mild to moderate depression (HDRS-17 ≤ 19)	Simvastatin 20mg	Atorvastatin 20mg	6 weeks	HDRS-17
Berk 2020 [42]	RCT, placebo-controlled	90 MDD patients, 15-25yo, baseline moderate to severe depression (MADRS ≥ 20)	TAU + rosuvastatin 10mg	TAU + placebo	12 weeks	MADRS
Ghanizadeh 2013 [39]	RCT, placebo-controlled	68 MDD patients, 17-70yo, baseline moderate to severe depression (HDRS-17 ≥ 17)	Fluoxetine (up to) 40mg + lovastatin 30mg	Fluoxetine (up to) 40mg + placebo	6 weeks	HDRS-17
Gougol 2015 [41]	RCT, placebo-controlled	48 MDD patients, 20-70yo, baseline moderate to severe depression (HDRS-17 ≥ 22)	Fluoxetine (up to) 40mg + simvastatin 20mg	Fluoxetine (up to) 40mg + placebo	6 weeks	HDRS-17
Haghighi 2014 [40]	RCT, placebo-controlled	60 MDD patients, 18-50yo, baseline severe depression (HDRS-21 ≥ 25)	Citalopram 40mg + atorvastatin 20mg	Citalopram 40mg + placebo	12 weeks	HDRS-21

CABG = Coronary Artery Bypass Graft; HDRS-17 = Hamilton Depression Rating Scale, 17 items; HDRS-21 = Hamilton Depression Rating Scale, 21 items; MADRS = Montgomery-Åsberg Depression Rating Scale; MDD = Major Depressive Disorder; RCT = Randomized Controlled Trial; TAU = Treatment As Usual (included case management, cognitive behavioural therapy, or pharmacotherapy).